CCO Infectious Disease Podcast
Long-Acting Lipoglycopeptides for Skin and Soft Tissue Infections : Implementation Into Practice
Episode Summary
Hear Kyle Molina, PharmD, BCIDP, discuss key considerations to ensure successful implementation of long-acting lipoglycopeptides for ABSSSI treatment into practice, such as justifying cost, targeting the right patient population, selecting between infusion locations, and maximizing institutional impact.
Episode Notes
In this episode, Kyle Molina, PharmD, BCIDP, discusses key considerations for successful implementation of long-acting lipoglycopeptides into clinical practice. Listen as he gives perspectives on:
- Reasons to consider use of long-acting lipoglycopeptides (eg, poor adherence to oral antibiotics, PICC-related costs and complications)
- Data supporting and challenging cost effectiveness of long-acting lipoglycopeptides
- Identifying the target patient population
- Selecting the right location to provide long-acting lipoglycopeptides
- Strategies to maximize institutional impact with key stakeholders (eg, hospital avoidance, reduced ED and hospital length of stay)
- Key characteristics of available long-acting lipoglycopeptides
- Addressing logistical challenges, including navigating the reimbursement process
Faculty:
Kyle Molina, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Scripps Green Hospital
La Jolla, California
Link to full program: